Compare CBAN & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | PEPG |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 317.6M |
| IPO Year | 1998 | 2022 |
| Metric | CBAN | PEPG |
|---|---|---|
| Price | $17.40 | $5.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 62.2K | ★ 839.5K |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 26.78 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $122,550,000.00 | N/A |
| Revenue This Year | $20.97 | N/A |
| Revenue Next Year | $25.65 | N/A |
| P/E Ratio | $10.99 | ★ N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $13.99 | $0.88 |
| 52 Week High | $18.41 | $6.72 |
| Indicator | CBAN | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 55.10 |
| Support Level | $17.00 | $5.04 |
| Resistance Level | $17.70 | $6.72 |
| Average True Range (ATR) | 0.36 | 0.57 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 82.25 | 34.91 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.